DJIA 17,156.85 24.88 0.15%
NASDAQ 4,562.19 9.43 0.21%
S&P 500 2,001.57 2.59 0.13%
market minute promo

Alnylam Pharmaceuticals (NASDAQ: ALNY)

77.69 4.23 (5.76%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ALNY $77.69 5.76%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $74.08
Previous Close $73.46
Daily Range $74.04 - $78.25
52-Week Range $47.03 - $112.57
Market Cap $5.9B
P/E Ratio -14.38
Dividend (Yield) $0.00 (0.0%)
Volume 964,637
Average Daily Volume 552,677
Current FY EPS -$5.37

Sector

Healthcare

Industry

Drugs

Alnylam Pharmaceuticals (ALNY) Description

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes. Website: http://www.alnylam.com/

News & Commentary

Growth and Dividends: Europe's Best Pharma Stock

Read below to find out which stock it is.

Alnylam Expands Pipeline with Preeclampsia Drug ALN-AGT - Analyst Blog

Tekmira: Much More Than An Ebola Treatment

Alnylam Broadens Pipeline With ALN-AGT, A Subcutaneously Administered RNAi Therapeutic Targeting Ang

Alnylam Broadens Pipeline With ALN-AGT, A Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen For The Treatment Of Hypertensive Disorders Of Pregnancy, Including Preeclampsia

ALNY Makes Notable Cross Below Critical Moving Average

Gilead: Let's Make A Deal

Alnylam Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ALNY

Alnylam's Q2 Loss Wider-than-Expected, Pipeline in Focus - Analyst Blog

New Analyst Biotech Stocks to Buy With Gigantic Implied Upside

Alnylam Pharmaceuticals Has Plenty On Its Plate

Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q2 2014 Results - Earnings Call Transcript

See More ALNY News...

ALNY's Top Competitors

ALNY $77.69 (5.76%)
Current stock: ALNY
AMGN $140.71 (0.99%)
Current stock: AMGN
GILD $103.84 (-0.88%)
Current stock: GILD
BIIB $327.58 (0.21%)
Current stock: BIIB